【簡介】 The 52nd edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information. Helpful in day-to-day practice and as a component of your organization's antimicrobial stewardship program, The Sanford Guide provides valuable guidance in the age of antibiotic resistance. Popular with physicians, pharmacists, physician assistants, nurse practitioners, and other clinicians. Coverage includes: Clinical syndromes (pathogens, bacterial, fungal, mycobacterial, parasitic viral), Anti-infective agents (dosing, pediatric adjustments, renal adjustments, adverse effects, activity, pharmacology, drug-drug interactions), Preventative therapy. What's new in 2022: Numerous changes throughout, with major changes in the following areas: New Drugs - Addition of new COVID-19 drugs, cefiderocol, ibrexafungerp, brincidofovir, cabotegravir, doravirine, and more. New Tables - ECMO Drug Dosing Adjustment (Table 10F) and QTc Prolongation (Table 10G). Table 1: Initial Choice of Antimicrobial Therapy - Numerous changes including 2021 CDC STI updates, recommendations for resistant infections. Table 5: Recommendations for MDR Bacteria - Updates for gram-negative bacilli updated based on recent evidence and IDSA Guidelines. Table 12: Treatment of Mycobacterial Infections - Revised recommendations for latent M. tuberculosis & non-tuberculous mycobacteria. Table 13: Treatment of Parasitic Infections - Significant changes to amebic meningoencephalitis, babesiosis and trypanosomiasis, and updates to sources for antiparasitic drugs (Table 13D). Table 14 - Updates to COVID recommendations (see digital content for latest information). 【目錄】